Stereoselective disposition of propranolol in rabbits: Role of presystemic organs and dose

Drug Metabolism and Disposition

Volumn 26, Issue 2, 1998, Pages 164-169

  Marier, Jean François ^b   Pichette, Vincent ^b   Du Souich, Patrick ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PLASMA PROTEIN; PROPRANOLOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; DRUG CLEARANCE; DRUG DISPOSITION; DRUG METABOLISM; ENANTIOMER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTESTINE; INTRAVENOUS DRUG ADMINISTRATION; LIVER; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEIN BINDING; RABBIT; STEREOCHEMISTRY;

ANIMALS; INTESTINES; KINETICS; LIVER; MALE; METABOLIC DETOXICATION, DRUG; PROPRANOLOL; RABBITS; STEREOISOMERISM;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 0031914764     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Barrett AM and Cullum VA (1968) The biological properties of the optical enantiomers of propranolol and their effects on cardiac arrhythmias. Br J Pharmacol 34:43-55.
2. du Souich P, Maurice H and Héroux L (1995) Contribution of the small intestine to the first-pass uptake and systemic clearance of propranolol in rabbits. Drug Metab Dispos 23:279-284.
3. Egginger G, Lindner W, Brunner G and Stoschitzky K (1994) Direct enantioselective determination of (R)- and (S)-propranolol in human plasma. Application to pharmacokinetic studies. J Pharm Biomed Anal 12:1537-1545.
4. Genco FM and Green JA (1986) β-blockers, in Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring (Evans WE, Schentag JJ and Jusko WJ eds) pp 735-781, Applied Therapeutics, Spokane, WA.
5. Gibaldi M and Perrier D (1982) Noncompartmental analysis based on statistical moment theory, in Pharmacokinetics (Swarbrick J ed) pp 409-418, Marcel Dekker, New York.
6. Hayes A and Cooper RG (1971) Studies on the absorption, distribution and excretion of propranolol in rat, dog and monkey. J Pharmacol Exp Ther 176:302-311.
7. Karim A and Piergies A (1995) Verapamil stereoisomerism: enantiomeric ratios in plasma dependent on peak concentration, oral input rate, or both. Clin Pharmacol Ther 58:174-184.
8. Krishna DR and Klotz U (1994) Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet 26:144-160.
9. Lalonde RL, Bottorf MB, Straka RJ, Tenero DM, Pieper JA and Wainer IW (1988) Nonlinear accumulation of propranolol enantiomers. Br J Clin Pharmacol 26:100-102.
10. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
11. Marathe PH, Shen DD and Nelson WL (1994) Metabolic kinetics of pseudo-racemic propranolol in human liver microsomes: enantioselectivity and quinidine inhibition. Drug Metab Dispos 22:237-247.
12. Olanoff LS, Walle T, Coward TD, Walle UK, Oexmann MJ and Conradi EC (1986) Food effects on propranolol systemic and oral clearance: support for a blood flow hypothesis. Clin Pharmacol Ther 40:408-414.
13. Olanoff LS, Walle T, Walle UK, Coward TD and Gaffney TE (1984) Stereoselective clearance and distribution of intravenous propranolol. Clin Pharmacol Ther 35:755-761.
14. Pang SK, Barker F III, Cherry WF and Goresky CA (1991) Esterases for enalapril hydrolysis are concentrated in the perihepatic venous region of the rat liver. J Pharmacol Exp Ther 257:294-301.
15. Pang SK, Cherry WF, Accaputo J, Schwab AJ and Goresky CA (1988) Combined hepatic arterial-portal venous and hepatic arterial-hepatic venous perfusions to probe the abundance of drug metabolizing activities: perihepatic venous O-deethylation activity for phenacetin and periportal sulphation for acetaminophen in the once-through rat liver preparation. J Pharmacol Exp Ther 247:690-700.
16. Pang SK, Schwab AJ, Goresky CA and Chiba M (1994) Transport, binding, and metabolism of sulphate conjugates in the liver. Chem Biol Interact 92:179-207.
17. Pang SK and Terrell JA (1981) Retrograde perfusion to probe the heterogeneous distribution of hepatic drug metabolizing enzymes in rats. J Pharmacol Exp Ther 216:339-346.
18. Rahn KH (1983) Haemodynamic effects of the optical isomers of beta receptor blocking agents. Eur Heart J 4(Suppl):27-30.
19. Ridell JG, Harron DW and Shanks RG (1987) Clinical pharmacokinetics of beta-adrenoreceptor antagonists: an update. Clin Pharmacokinet 12:305-320.
20. Silber B, Holford NHG and Riegelman S (1986) Stereoselective disposition and glucuronidation of propranolol in humans. J Pharm Sci 71:699-703.
21. Spanh-Langguth H, Podkowic H, Stahl E, Martin E and Mutschler E (1991) Improved enantio-specific RP-HPLC assays for propranolol in plasma and urine with pronethalol as internal standard. J Anal Toxicol 15:327-331.
22. Stoschitzky K and Lindner W (1990) Spezifische und unspezifische Wirkungen von Beta-Rezeptorenblockern: stereoselektiv unterschiedliche Eigenschaften am Beispiel von (R)- und (5)-Propranolol. Wien Med Wochenschr 140:156-162.
23. Stoschitzky K, Lindner W, Egginger G, Brunner F, Obermayer-Pietsch B, Passath A and Klein W (1992) Racemic (R,S)-propranolol versus half-dosed optically pure (S)-propranolol in humans at steady state: hemodynamic effects, plasma concentrations, and influence on thyroid hormone levels. Clin Pharmacol Ther 51:445-453.
24. Von Bahr C, Hermansson J and Tawara K (1982) Plasma levels of (+)- and (-)-propranolol and 4-hydroxypropranolol after administration of racemic (±)-propranolol in man. Br J Clin Pharmacol 14:79-82.
25. 1acid glycoprotein and albumin. Clin Pharmacol Ther 34:718-723.
26. Walle T, Wilson MJ, Walle UK and Bai SA (1983b) Stereochemical composition of propranolol metabolites in the dog using stable isotope-labelled pseudoracemates. Drug Metab Dispos 11:544-549.
27. Walpole HE, Lee WM, Walle T, Walle UK, Wilson MJ and Kennedy JW (1990) Rabbit bepatocytes in primary culture: preparation, viability and use in studies of propranolol metabolism. Hepatology 11:394-400.